Skip to main content
. 2022 Nov 2;9:922696. doi: 10.3389/fcvm.2022.922696

TABLE 2.

Comparison of baseline characteristics and procedural data between groups.

Patient number, n 498
SAPIEN 3
n = 352
SAPIEN 3 Ultra
n = 146
P-value
Age (years) 80.6 ± 5.73 80.7 ± 5.29 0.864
Female, n (%) 171 (48.5%) 81 (55.5%) 0.324
BMI (kg/m2) 26.7 ± 5.25 26.3 ± 4.8 0.921
Hypertension, n (%) 304 (86%) 101 (69.2%) 0.107
Diabetes, n (%) 94 (26%) 31 (21.2%) 0.791
Dyslipidemia, n (%) 176 (50%) 74 (51%) 0.887
NYHA class III or IV, n (%) 190 (54%) 76 (52%) 0.789
COPD, n (%) 91 (25.8%) 26 (17.8%) 0.146
Previous MI, n (%) 49 (14%) 23 (16%) 0.546
GFR (mL/min/1.73 m2) 54.9 ± 19.85 52.2 ± 19.48 0.246
Logistic Euroscore II 4.8 ± 4.5 4.33 ± 4.7 0.2658
STS score 3.7 ± 3.5 3.2 ± 3.4 0.346
AF, n (%) 61 (17%) 20 (14%) 0.360
RBBB at baseline, n (%) 32 (9%) 19 (13%) 0.213
PR interval, ms 168 ± 38.9 175 ± 34.6 0.673
QRS duration, ms 101 ± 25.4 102 ± 23.8 0.854
Moderate or severe LVOT calcium n (%) 74 (21%) 32 (22%) 0.843
Membranous septum length (mm) 4.1 ± 2.4 4.2 ± 2.4 0.886
Calcification (grade) 2.35 ± 0.9 2.4 ± 0.94 0.577
Annulus area (mm2) 461 ± 85.4 454 ± 83 0.401
Echocardiography data
LV ejection fraction (%) 58.4 ± 10.9 60.6 ± 10.3 0.069
Transvalvular mean aortic gradient (mmHg) 45.6 ± 15.2 46.6 ± 13.5 0.501
Transvalvular maximum aortic gradient (mmHg) 74.3 ± 23 74.8 ± 20.3 0.933
Previous medication
Beta blockers, n (%) 182 (51%) 61 (42%) 0.148
Calcium channel blockers, n (%) 81 (23%) 36 (24.7%) 0.730
Amiodarone, n (%) 39 (11%) 14 (9.5%) 0.642
Procedural data
Percutaneous access
Transfemoral 331 (94%) 140 (95.9%) 0.819
Transapical 16 (4.5%) 4 (2.7%) 0.270
Transaortic 5 (1.4%) 2 (1.4%) 0.923
Prosthesis size
26 mm 207 71 0.166
23 mm 142 75 0.089
20 mm 3 0 0.264
Predilatation, n (%) 37 (10.5%) 16 (11%) 0.889
Postdilatation, n (%) 33 (9.3%) 12 (8%) 0.696
Postprocedural PR interval, ms 185 ± 39.4 178 ± 35.6 0.784
Postprocedural QRS duration, ms 111 ± 26.3 110 ± 28.6 0.811
Prosthesis implantation depth (mm) 4.89 ± 1.57 4.47 ± 1.36 0.001